Anupam Rasayan India Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nqr5nnjs76i2337jjrcnxbhn.pdf

Key Takeaways


Demand Environment

Vishal Thakkar: "I would put it very simply, two plus two plus two, two years for getting into LOI, two years from LOI to commercialization, another two years for commercialization to ramp up."

Revenue Drivers & LOI Pipeline

Vishal Thakkar: "So, we do not see any major competitive intensity on this side."

Inventory & Working Capital

Vishal Thakkar: "when I sell it out, that converts into revenue and gets into my denominator as well. So, when you do numerator reduction and denominator addition, you will see that the numbers will start getting more representative."

Margins & Returns

Vishal Thakkar: "So, let's say today in this market I would say 25% to 27% of EBITDA margin that I would be comfortable with guidance. Though we have delivered a little better, but on a consol basis that's kind of a number I would go by."

Balance Sheet & Capex


Technology & New Chemistries


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue recoveryNumbers to be better from Q3 with increased pharma and polymer contributionQ3 FY25
Growth normalizationFY26 should return to the growth journey seen in the pastFY26
Inventory normalizationInventory numbers similar to historical levels around FY21, FY23Next 18-24 months
Inventory liquidationInventory to get liquidated, significant reduction from FY24 levelsNext 2-4 quarters; meaningfully by FY26
Capex completionBalance capex to be completedNext two quarters (FY25)
Debt repayment~₹200-plus cr repaid from pref and warrant proceeds; term debt largely doneH1 FY26
Working capital improvementSignificant improvement vs FY25FY26
Japan revenue share~1/3 of sales from Japan, majority under long-term contractsWithin 2-3 years
LOI annualized revenue₹1,200-1,400 cr from LOI productsMedium term
Standalone revenue target~₹3,000 cr from standalone business based on current portfolioMedium term (3-4 years)
Pharma revenue contributionIn the 20s percentage rangeMedium term
EBITDA margin25-27% on consolidated basisOngoing

Key Metrics

MetricQ2 FY25
Operating revenue₹294 cr, 16% higher than Q1 FY25 and ~25% lower than Q2 FY24
H1 FY25 operating revenue₹548 cr, ~30% down vs same period last financial year
EBITDA including other income₹82 cr, down 26% YoY from ₹111 cr in Q2 FY24
EBITDA margin28%, vs 28% in Q2 FY24
H1 FY25 EBITDA margin25.5%
Profit after tax₹31 cr, degrowth of 37% YoY from ₹49 cr
PAT margin~10% of top line
H1 FY25 PAT₹43 cr, degrowth of 58% YoY from ₹101 cr
Top 10 customer concentration91% of revenue
CAPEX completed as of Sep 30, 2024₹610 cr, remaining to be completed over next two quarters in FY25
Total LOI value~₹9,000 cr, implying ₹1,400–1,500 cr revenue over average 5–6 year contract period
Annualized revenue expectation from LOI products₹1,200–1,400 cr over the next medium term
Tanfac plant capacity29,730 MT, expanded from 14,150 MT and commissioned from October 2024
Green energy share of electricity needs65%, from combined 27.1 MW hybrid power projects saving ~₹28 cr annually
Standalone net debt~₹1,200 cr as of September 2024